The European Lung Cancer Conference 2016 (ELCC 2016), is the most important conference in Europe for all clinical practitioners involved in the diagnostic work-up and treatment of lung cancer and other thoracic malignancies.
It brings together a unique community of medical professionals to facilitate the advancement of a personalised approach to the management of lung and other thoracic cancers and the implementation of new discoveries into clinical practice.
Fast facts: ELCC 2016
- Expecting over 1600 international participants
- Specialists and Key Opinion Leaders (KOLs) from all over the world in one place and as one community
- 16 educational and 4 key note lectures sessions running over four days
- An internationally renowned faculty
- 8 Industry Satellite Symposia
- Vibrant commercial exhibition
- Excellent networking opportunities
Past attendance
ESMO gratefully acknowledges the valuable contribution of the following organisations in the ELCC Conferences over the years.
Past attendees | ||
Abbott Laboratories |
Daiichi Sankyo Europe |
Novartis Oncology |
AbbVie |
Eli Lilly |
Olympus Medical Systems Europe |
Agennix |
Elsevier |
Otsuka Pharmaceuticals |
Amgen |
GE Healthcare |
Pfizer Oncology |
Astrazeneca |
GSK |
Qiagen |
Bayer Schering Pharma |
Helsinn Healthcare |
Roche |
Bristol-Myers Squibb |
Karl Storz |
Rosetta Genomics |
Boehringer Ingelheim |
Merck Serono |
Sanofi |
Clovis Oncology |
Microsulis Medical Ltd. |
Varian Medical Systems |
Cis Bio International |
MSD |
Wisepress Ltd |
How can I participate in ELCC 2016?
At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our conferences.
Contact the ESMO Events Sponsorship Team for more details. We look forward to hearing from you!